CareDx, Inc. Tech Stack

CareDx, Inc. uses 8 technology products and services including Atlassian, Ansible, CookieYes, and more. Explore CareDx, Inc.'s tech stack below.

  • Atlassian
    Application Development & Management
  • Ansible
    Configuration Management
  • CookieYes
    Cookie Compliance
  • Hammer.js
    Javascript Libraries
  • Module Federation
    Miscellaneous
  • BambooHR
    Recruitment Marketing
  • OWASP
    Security
  • Apache
    Web Servers

Media & News

CareDx, Inc.'s Email Address Formats

CareDx, Inc. uses at least 4 format(s):
CareDx, Inc. Email FormatsExamplePercentage
first.last@caredx.comJohn.Doe@caredx.com
44%
lfirst@caredx.comDJohn@caredx.com
25%
firstlast@caredx.comJohnDoe@caredx.com
19%
filast@caredx.comJoDoe@caredx.com
12%

Frequently Asked Questions

Where is CareDx, Inc.'s headquarters located?

Minus sign iconPlus sign icon
CareDx, Inc.'s main headquarters is located at 8000 Marina Blvd Brisbane, California 94005 US. The company has employees across 6 continents, including North AmericaEuropeOceania.

What is CareDx, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact CareDx, Inc.'s main corporate office by phone at +1-415-287-2300. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CareDx, Inc.'s stock symbol?

Minus sign iconPlus sign icon
CareDx, Inc. is a publicly traded company; the company's stock symbol is CDNA.

What is CareDx, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
CareDx, Inc.'s official website is caredx.com and has social profiles on LinkedIn.

How much revenue does CareDx, Inc. generate?

Minus sign iconPlus sign icon
As of March 2024, CareDx, Inc.'s annual revenue reached $750M.

What is CareDx, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
CareDx, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CareDx, Inc. have currently?

Minus sign iconPlus sign icon
As of March 2024, CareDx, Inc. has approximately 651 employees across 6 continents, including North AmericaEuropeOceania. Key team members include Chief Executive Officer: R. C.Chief Of Staff To The Ceo: S. S.Chief Digital And Patient Officer At Caredx, Inc: K. R.. Explore CareDx, Inc.'s employee directory with LeadIQ.

What industry does CareDx, Inc. belong to?

Minus sign iconPlus sign icon
CareDx, Inc. operates in the Biotechnology Research industry.

What technology does CareDx, Inc. use?

Minus sign iconPlus sign icon
CareDx, Inc.'s tech stack includes AtlassianAnsibleCookieYesHammer.jsModule FederationBambooHROWASPApache.

What is CareDx, Inc.'s email format?

Minus sign iconPlus sign icon
CareDx, Inc.'s email format typically follows the pattern of first.last@caredx.com. Find more CareDx, Inc. email formats with LeadIQ.

How much funding has CareDx, Inc. raised to date?

Minus sign iconPlus sign icon
As of March 2024, CareDx, Inc. has raised $164M in funding. The last funding round occurred on Jan 21, 2021.
CareDx, Inc.

CareDx, Inc.

Biotechnology ResearchCalifornia, United States501-1000 Employees

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

NASDAQ:CDNA

About AlloSure®

AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. 

http://www.allosure.com/


About AlloMap® 

AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

http://www.allomap.com/

Section iconCompany Overview

Headquarters
8000 Marina Blvd Brisbane, California 94005 US
Phone number
+1-415-287-2300
Website
caredx.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
CDNA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
501-1000

Section iconFunding & Financials

  • $164M

    CareDx, Inc. has raised a total of $164M of funding over 18 rounds. Their latest funding round was raised on Jan 21, 2021.

  • $100M$1B

    CareDx, Inc.'s revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $164M

    CareDx, Inc. has raised a total of $164M of funding over 18 rounds. Their latest funding round was raised on Jan 21, 2021.

  • $100M$1B

    CareDx, Inc.'s revenue is in the range of $100M$1B

© LeadIQ, Inc. All rights reserved.